Cancer Q&A with HOA: Clinical Trials Awareness
(WSYR-TV) — When it comes to your health, there are three words you never want to hear, and that's 'you have cancer.' But, if that time does ever come, Hematology-Oncology Associates of CNY is here to help.
Dr. Ajeet Gajra joined the show to talk about Clinical Trials Awareness Month during the month of May.
Dr. Gajra explored the following questions:
Can you explain what clinical trials are and why they're so important, especially in cancer care?
What types of clinical trials are currently being offered at Hematology-Oncology Associates of CNY, and who is eligible to participate?
There's often some hesitation or fear around clinical trials—what are some of the most common misconceptions you hear from patients, and how do you address them?
How do clinical trials benefit not just individual participants, but the broader community and future generations of cancer patients?
For viewers who may be interested in learning more or getting involved, what's the best way to start the conversation about participating in a clinical trial?
Learn more about Hematology-Oncology Associates of CNY at hoacny.com. You can also email clinicaltrials@hoacny.com or call (315) 472-7504 ext. 1350.
Head to Cancer.gov/TrialGuide or call 1-800-4-CANCER for information on clinical trials.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Heat Related Dangers this Summer
(SOUTHERN COLORADO) — As we enter the summer months, high temperatures are only going to continue climbing. June marks the start of the Meteorological Summer, and it's the time of year when we begin to see temperatures consistently reaching the upper-80s, and in some parts of Southern Colorado, even the 90s. In a region as active as Southern Colorado, it's no surprise that more and more people will be heading outside. Whether it's hiking, running, walking, or just enjoying the outdoors, summer is when the outdoors really come alive. But with that increased time outside comes an important reminder and message: heat can be dangerous. As temperatures rise and outdoor activity increases, so do the risks. It's essential to recognize that heat isn't just uncomfortable, it can be deadly. In fact, heat-related deaths are the number one weather-related killer, and that number has only been growing. Over the last 20 years, data shows a steady increase in these deaths, with average yearly numbers continuing to climb over the past five years on average. The most effective way to prevent heat-related illness and deaths is through awareness. Understanding the signs of heat exhaustion and heat stroke can make all the difference. These are two distinct heat-related conditions, but both are extremely serious. Recognizing the warning signs early and taking the right precautions could truly save a life. As we enjoy all that summer has to offer, don't forget to take care of yourself and those around you. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hamilton Spectator
an hour ago
- Hamilton Spectator
UPDATE - Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
HENDERSON, Nev., June 12, 2025 (GLOBE NEWSWIRE) — Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by , on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ET LINK: REGISTER HERE Available for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on . Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS: Nika Pharmaceuticals, Inc. Name Clifford P. Redekop Title Corporate Secretary Phone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 johnv@
Vogue
an hour ago
- Vogue
Everything You Need to Know About the New Breast Cancer Vaccine
In the search for a cure for breast cancer, a major breakthrough has finally come. Biotechnology company Anixa Biosciences, Inc. announced earlier this month that its breast cancer vaccine, which is being designed with the help of the Cleveland Clinic, has completed phase 1 of its clinical testing. It will be moving forward to the next stages of development, and if all goes to plan, doctors may soon be able to stop cancerous tumors from forming. 'The vaccine is designed to mobilize the patient's immune system to find, recognize, and destroy breast cancer cells for primary prevention,' Amit Kumar, Ph.D, CEO of Anixa Biosciences, Inc., tells Vogue. 'If a patient is vaccinated and [their] immune system is trained to destroy the cancer cells when the cancer appears, the vaccinated immune system will destroy the cells before they can grow into a cell tumor.' The vaccine, which comes in a set of three shots given to patients two weeks apart, specifically targets alpha-lactalbumin, a milk protein that is produced during lactation. It is typically not found after lactation in normal breast tissue, but scientists have found that the protein is expressed in about 70% of triple-negative breast cancer (TNBC) cases. The hope, Rima Patel, MD, oncologist and assistant professor in the division of hematology and medical oncology at Mount Sinai, explains, is that the vaccine can train people's immune system to recognize the protein as harmful and attack it before it turns into cancer. 'It is designed to alert the immune system to attack a breast tumor, before it can develop or recur, and prevent it from growing,' says Dr. Patel. 'It has been studied in an early phase 1 clinical trial in 35 women who had a history of early-stage TNBC and are at high risk of recurrence, and in patients without a history of cancer but are at high risk of developing breast cancer due to a genetic predisposition or other factors. The study thus far showed that the vaccine is overall well tolerated and resulted in an immune response in most patients.' Research in mice shows that the vaccine has been successful in activating the immune system against alpha-lactalbumin and preventing breast tumors in these small creatures. While the vaccine shows promise in humans, Dr. Kumar says they have to test larger numbers and with control groups in the next phases to show its efficacy and safety.
